Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time. A new collaboration between artificial intelligence drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed molecules against "undruggable" cancer targets.  The research will test 15 to 20 undruggable targets - but are they undruggable? And how does AI work in the drug discovery process? This week, we have a conversation with Kyle Tretina, Alliance Manager of AI Platforms at Insilico Medicine, on a wide range of subjects including drug discovery, undruggable targets, the collaboration with the University of Toronto, and more. 00:58-05:11: About Insilico Medicine 05:11-06:09: Why is AI in the news? 06:09-07:39: Helping people through AI 07:39-09:10: What is Insilico Medicine doing with AI? 09:10-10:15: Does Insilico Medicine take drugs from idea to trials? 10:15-11:32: How do your partnerships come about? 11:32-19:34: How does drug development start with AI? 19:34-24:43: Can AI address undruggable targets? 24:43-25:05: What do you need to do after finding a potential drug? 25:05-27:57: Can quantum computing aid drug development? 27:57-30:13: How can AI help reduce costs and save time? 30:13-32:56: What is your partnership with the University of Toronto? 32:56-36:24: What is the timescale for introducing drugs from AI? 36:24-37:29: What conditions are you working on? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter